CyBeR Association in Relapsed/Refractory DLBCL

Participants will received 6 cycles every 21 days with a follow-up period of 24 months. CT-Scan after 3 cycles and at the end of the treatment will be used to assess treatment response, established with Cheson criteria in 1999. Principal objective is to obtain an overall response rate of 60% (corresponding to an increased of 15% of the rituximab-gemcitabine-oxaliplatine regimen's overall response rate). Secondaries objectives are to value toxicity, progression free survival and overall survival.